"What do these percentages mean? I believe you posted that the <60 eGFR amounts to a 50% RRR."

In the baseline eGFR <60 population, there were 124 patients treated with apabetalone who experienced 13 first occurence 3-point MACE events (10.4% event rate). There were 164 patients treated with placebo who experienced 35 first occurence 3-point MACE events (21.3% event rate).  The 10.4% vs. 21.3% event rates gets you the ~50% RRR. Numbers don't add up, actually seems like 51% RRR. Close enought.

In the baseline eGFR ≥ 60 population, there were 1084 patients treated with apabetalone who experienced 112 first occurence 3-point MACE events (10.3% event rate). There were 1041 patients treated with placebo who experienced 114 first occurence 3-point MACE events (11.0% event rate).  The 10.3% vs. 11.0% event rates gets you the ~6% RRR.

BDAZ